Showing results (91-100 of 141) with videos related to
Sort By:
Pageof 15
Journal of Crohn'S & Colitis|November 7, 2023
Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel DiseaseXavier Roblin, Stéphane Nancey, Konstantinos Papamichael, et al.Annals of Gastroenterology|January 6, 2022
The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel diseaseFotios S Fousekis, Konstantinos Papamichael, Georgios Kourtis, et al.Inflammatory Bowel Diseases|July 2, 2024
Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous VedolizumabRachel Porth, Tina Deyhim, Samantha Zullow, et al.Inflammatory Bowel Diseases|August 26, 2025
Long-term Outcomes of Patients with Crohn's Disease Treated with RisankizumabGrace Geeganage, Ajay Gade, Alessandra Saraga, et al.Inflammatory Bowel Diseases|September 26, 2024
Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel DiseaseRachel Porth, Tina Deyhim, Grace Geeganage, et al.European Journal of Gastroenterology & Hepatology|September 8, 2016
Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatmentLucas Wauters, Thomas Billiet, Konstantinos Papamichael, et al.Journal of Crohn'S & Colitis|May 1, 2015
Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease RecurrenceMarc Ferrante, Konstantinos Papamichael, Dana Duricova, et al.Digestive Diseases and Sciences|December 9, 2025
Proactive Compared to Reactive Therapeutic Drug Monitoring Is Associated with Less Treatment Failure in Patients with Inflammatory Bowel Disease Treated with AdalimumabAjay Gade, Alessandra Saraga, Tina Deyhim, et al.Journal of Pediatric Gastroenterology and Nutrition|February 20, 2024
Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel diseaseNaamah Zitomersky, Lisa Chi, Enju Liu, et al.Journal of Clinical Medicine|May 27, 2023
Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel DiseaseXavier Roblin, Gérard Duru, Konstantinos Papamichael, et al.Pageof 15